论文部分内容阅读
目的观察孟鲁斯特纳治疗小儿呼吸道合胞病毒肺炎的效果。方法选择2011年1月—2013年10月我院收治的呼吸道合胞病毒肺炎患儿88例,随机分为对照组和治疗组各44例入院后患儿均给予吸氧、抗病毒、吸痰等对症治疗。对照组给予更昔洛韦5 mg/kg加入100 ml生理盐水静脉滴注,2次/d;治疗组在对照组基础上给予孟鲁斯特纳,<6个月2 mg,6~18个月4 mg,>18个月5 mg,1次/d。均治疗14 d评价症状体征改善时间、疗效及不良反应。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果总有效率对照组70.45%,治疗组97.73%,两组比较差异有统计学意义(P<0.05)。治疗组发热消失时间、咳嗽消失时间、啰音消失时间、住院时间[(6.5±2.0)、(7.2±1.5)、(6.7±2.4)、(7.0±2.3)d]均短于对照组[(2.3±1.0)、(4.3±1.0)、(3.5±1.7)、(4.6±2.1)d],两组比较差异均有统计学意义(均P<0.05)。对照组不良反应发生率为10.17%,观察组为8.47%,两组比较差异无统计学意义(P>0.05)。结论儿童清肺口服液治疗小儿呼吸道合胞病毒肺炎可迅速改善患儿症状体征,提高临床疗效,缩短住院时间,值得临床应用。
Objective To observe the effect of Montelukast on children with respiratory syncytial virus pneumonia. Methods Eighty-eight children with respiratory syncytial virus pneumonia admitted in our hospital from January 2011 to October 2013 were randomly divided into control group and treatment group, and 44 children in each group were given oxygen, antivirus and suctioning Symptomatic treatment. The control group was treated with ganciclovir 5 mg / kg by intravenous drip of 100 ml normal saline twice a day for 6 months in the control group Month 4 mg,> 18 months 5 mg, 1 time / d. The 14-day evaluation of symptoms and signs to improve the time, efficacy and adverse reactions. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 70.45% in the control group and 97.73% in the treatment group, with significant difference between the two groups (P <0.05). The disappearance of fever, the disappearance of cough, the time of rales disappearance, and the length of hospital stay [(6.5 ± 2.0), (7.2 ± 1.5), (6.7 ± 2.4) and (7.0 ± 2.3) d] 2.3 ± 1.0), (4.3 ± 1.0), (3.5 ± 1.7) and (4.6 ± 2.1) d respectively. There were significant differences between the two groups (all P <0.05). The incidence of adverse reactions in the control group was 10.17% and in the observation group was 8.47%. There was no significant difference between the two groups (P> 0.05). Conclusion Children Qingfei oral solution for children with respiratory syncytial virus pneumonia can rapidly improve children’s symptoms and signs, improve clinical efficacy and shorten the hospital stay, is worth clinical application.